Oxford PharmaGenesis insights into best practices for the planning and communication of real-world evidence (RWE) studies have been highlighted in an invited editorial, published online in the Journal of Comparative Effectiveness Research (http://www.futuremedicine.com/doi/full/10.2217/cer-2016-0070). Authored by Commercial Director Dr Richard White, the article – titled ‘Building trust in real-world evidence and comparative effectiveness research: the need for transparency’ – identifies key concerns raised over the robustness of RWE studies and provides recommendations on how to address them.
“RWE studies are increasingly required to support the licensing, reimbursement and utilization of health interventions, yet RWE is often mistrusted and considered to be less robust than evidence from randomized controlled trials,” said Richard. “Work needs to be done to break down the current barriers to acceptance of RWE in informing healthcare decision-making, and this article summarizes some of the steps we feel can be taken to achieve this through increased transparency in RWE study planning and communication.”
Oxford PharmaGenesis is recognized as a leader in planning and realizing the communication of data from RWE and health economics and outcomes research studies, and has delivered award-winning presentations on this subject at recent international meetings of The International Publication Planning Association (TIPPA) and the International Society for Medical Publication Professionals (ISMPP). Click here for further information on our specialist real-world evidence capabilities. See below a short extract from a recent presentation, in which Richard illustrates the main issues discussed in his article and elaborates on the possible solutions.
